China’s Innovative Drugs Expand Global Reach as Overseas Licensing Deals Exceed $120 Billion
Dragon Media News Desk
China’s homegrown innovative drugs have gained wider international reach this year, reflecting growing global recognition of the country’s pharmaceutical research and development capabilities, according to the National Medical Products Administration.
The total value of overseas licensing agreements involving innovative Chinese drugs has exceeded $120 billion this year, representing a 36 percent increase from a year earlier. Upfront payments under these agreements have surpassed $10 billion, while the average value of individual deals has also continued to rise.
The figures were released during the launch of a nationwide drug safety awareness week. China’s drug regulator said regulatory reforms in recent years have focused on improving pharmaceutical quality, accelerating innovation and creating a more efficient pathway for promising new treatments to reach the market.
In 2025, more than 2,900 clinical trials for new drugs were registered across China, an 18 percent year-on-year increase and a record high. Clinical trials involving cell and gene therapies rose by about 30 percent, highlighting strong activity in advanced areas of biomedical research.
Regulatory reforms have also contributed to a growing number of innovative products receiving market approval. Since the beginning of 2026, China has approved 59 innovative drugs and 51 innovative medical devices, including 13 first-in-class medicines based on new mechanisms of action or novel biological targets.
China’s expanding pharmaceutical innovation ecosystem is also drawing greater investment from multinational companies. Global drugmakers have been building or expanding research and development centers and manufacturing facilities in the country as they seek to tap into its large market, research capacity and increasingly sophisticated healthcare sector.
In March, US pharmaceutical company Eli Lilly announced plans to invest $3 billion in China over the next decade. The investment is aimed at expanding supply-chain and production capacity, particularly as demand grows for treatments for type 2 diabetes and obesity.
The move marked another significant step in Eli Lilly’s long-term expansion in China and reflected wider confidence among multinational pharmaceutical companies in the country’s healthcare and life-sciences market.
The National Medical Products Administration said it would further improve communication mechanisms for early-stage drug development, provide tailored regulatory guidance for key products and maintain expedited testing channels to support pharmaceutical innovation.
The combination of rising clinical-trial activity, growing approvals of innovative medicines, expanding overseas licensing deals and stronger multinational investment indicates that China’s pharmaceutical sector is moving beyond its traditional role as a manufacturing base and emerging as an increasingly important global source of drug innovation and medical technology.
